Whales with a lot of money to spend have taken a noticeably bearish stance on Viking Therapeutics.
Looking at options history for Viking Therapeutics VKTX we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 0% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $58,850 and 6, calls, for a total amount of $325,150.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $35.0 and $85.0 for Viking Therapeutics, spanning the last three months.
Insights into Volume & Open Interest
In today's trading context, the average open interest for options of Viking Therapeutics stands at 1630.57, with a total volume reaching 975.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $35.0 to $85.0, throughout the last 30 days.
Viking Therapeutics Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | NEUTRAL | 02/21/25 | $8.1 | $7.1 | $7.6 | $85.00 | $152.0K | 104 | 200 |
| VKTX | CALL | TRADE | NEUTRAL | 02/21/25 | $24.7 | $23.3 | $24.0 | $40.00 | $60.0K | 92 | 25 |
| VKTX | PUT | SWEEP | BEARISH | 01/17/25 | $9.8 | $9.6 | $9.8 | $50.00 | $33.3K | 869 | 36 |
| VKTX | CALL | TRADE | BEARISH | 09/20/24 | $3.5 | $3.0 | $3.2 | $70.00 | $32.0K | 7.0K | 18 |
| VKTX | CALL | TRADE | NEUTRAL | 09/20/24 | $2.95 | $2.65 | $2.8 | $70.00 | $28.0K | 7.0K | 547 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Present Market Standing of Viking Therapeutics
- Trading volume stands at 1,102,817, with VKTX's price up by 0.76%, positioned at $56.19.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 75 days.
Expert Opinions on Viking Therapeutics
In the last month, 2 experts released ratings on this stock with an average target price of $104.0.
- An analyst from Raymond James persists with their Strong Buy rating on Viking Therapeutics, maintaining a target price of $118.
- An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $90.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
